Antiverse raises £1.4m in seed funding to advance its AI drug discovery platform.
.png)
The seed round was supported by a syndicate of investors including the Development Bank of Wales and the UKI2S Innovate Accelerator to fund platform development and laboratory expansion.
Antiverse is a techbio company that uses artificial intelligence and in-house laboratories to design therapeutic antibodies for complex disease targets. Headquartered in Cardiff, the firm develops treatments for conditions involving challenging molecular structures.
Antiverse has secured £1.4m in a seed funding round backed by a syndicate of investors including the Development Bank of Wales and the UKI2S Innovate Accelerator. The capital will be deployed to advance the company's computational drug discovery technology and expand operations.
Additional participants in the raise included the Angel Co-Investment Fund, Tensor Ventures, Wren Capital, Ed Parkinson, Cambridge Angels, and SyndicateRoom. The proceeds will also support the construction of a new laboratory in Cardiff and the recruitment of specialist machine learning engineers, laboratory scientists, and structural biologists.
From the founder
"Our investors recognise the potential of our AI-powered antibody drug discovery platform to provide a breakthrough in the industry. With our technology, it will be possible to develop drugs for difficult targets and ultimately reduce drug discovery timescales from years to weeks. In addition to platform development, the funding will enable us to invest in facilities and recruitment; we are grateful to our investors and Innovate UK for their continued support."
Murat Tunaboylu
Co-Founder and CEO at Antiverse
Investor perspective
"Antiverse has an ambitious team of AI experts and scientists with a vision to transform drug discovery. This is a great example of a world class business taking off in Wales with the support of the Development Bank of Wales."
Ed Parkinson
lead investor for the syndicate of Angel Investors, Ed Parkinson
Use of funds
- 01Grow the team
- 02Continue product development
- 03Build out infrastructure
Investors
Ed Parkinson
Ed Parkinson
Rafael Joseph
Development Bank of Wales
UKI2S Innovate Accelerator
Angel Co-Investment Fund
Martin Drdul
Tensor Ventures
Wren Capital
Cambridge Angels
SyndicateRoom
.png)